Current and projected future economic burden of Parkinson’s disease in the U.S.

Abstract

Parkinson’s disease (PD) is one of the world’s fastest growing neurological disorders. Much is unknown about PD-associated economic burdens in the United States (U.S.) and other high-income nations. This study provides a comprehensive analysis of the economic burdens of PD in the U.S. (2017) and projections for the next two decades. Multiple data sources were used to estimate the costs of PD, including public and private administrative claims data, Medicare Current Beneficiary Survey, Medical Expenditure Panel Survey, and a primary survey ( n = 4,548) designed for this study. We estimated a U.S. prevalence of approximately one million individuals with diagnosed Parkinson’s disease in 2017 and a total economic burden of $51.9 billion. The total burden of PD includes direct medical costs of $25.4 billion and $26.5 billion in indirect and non-medical costs, including an indirect cost of $14.2 billion (PWP and caregiver burden combined), non-medical costs of $7.5 billion, and $4.8 billion due to disability income received by PWPs. The Medicare program bears the largest share of excess medical costs, as most PD patients are over age 65. Projected PD prevalence will be more than 1.6 million with projected total economic burden surpassing $79 billion by 2037. The economic burden of PD was previously underestimated. Our findings underscore the substantial burden of PD to society, payers, patients, and caregivers. Interventions to reduce PD incidence, delay disease progression, and alleviate symptom burden may reduce the future economic burden of PD.

Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US

“…Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting more than 1 million Americans at a cost to society of more than $50 Billion dollars 1,2 . While PD is typically defined clinically by four cardinal motor symptoms that include resting tremor, bradykinesia, rigidity and postural instability 3 , the symptoms of PD are broader.…”

Peripheral Glycolysis in Neurodegenerative Diseases

“…The prevalence of this chronic disease is growing faster than AD, doubling between 1990 and 2015, and predicted to double again by 2040 [ 52 ]. The growing number of cases poses an alarming economic concern with direct medical costs in the US estimated to be in excess of $25 billion in 2017 [ 53 ]. The majority of treatments available for PD revolve around the replacement of the lost dopamine as dopaminergic neurons degenerate.…”

Advances and Perspectives in Dental Pulp Stem Cell Based Neuroregeneration Therapies

“…Neuroregenerative therapies have always been a priority for health research in developed countries due the overwhelming social, economic and dependency burdens suffered by both the affected patients and their close relatives [ 1 , 2 , 3 ]. The nervous system in humans possesses a very limited capacity of self-repair in the event of injury.…”